GenScript boosts synthetic biology with CustomArray buy

With its acquisition of DNA chip player CustomArray, GenScript is adding new capabilities in CRISPR, protein and antibody engineering to its stable.

Gene synthesis player GenScript is adding new synthetic biology capabilities—in areas such as CRISPR and antibody engineering—with a buyout of CustomArray.

Based in Bothell, Washington, CustomArray offers oligonucleotide pools and DNA microarrays—also called DNA chips or biochips—for applications including DNA libraries and targeted sequencing, as well as CRISPR and protein and antibody engineering. The terms of the deal were not disclosed.

"The acquisition of CustomArray further strengthens our synthetic biology product portfolio with a unique technology that we believe will enhance our customers' ability to accelerate innovation in drug discovery and development, genome editing, protein engineering, and synthetic biology," said GenScript CEO Frank Zhang, Ph.D., in a statement.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

CustomArray’s semiconductor chip tech allows it to synthesize DNA directly on the chip surface; it can create thousands of oligonucleotides simultaneously in a high-density and cost-effective way, the company says.

“We are excited to join the GenScript team and excited to capitalize on the opportunity to bring our technology to a much broader range of customers and applications than we could ever reach on our own,” said CustomArray CEO Brooke Anderson. “We look forward to providing products to innovators in the fields of genome editing, biomaterials, agriculture, and more."

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

Five years after Congress passed a law to reduce unnecessary MRIs and CT scans, federal officials have yet to implement it.